Related Experiment Video
Updated: Sep 2, 2025
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.3K
Biomarkers for Atopic Dermatitis in Children
1Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Pediatric Allergy, Immunology, and Pulmonology
|August 4, 2022
Summary
This review examines circulating biomarkers for atopic dermatitis (AD) severity. Key inflammatory markers like thymus and activation-regulated chemokine (CCL17) and thymic stromal lymphopoietin show promise for assessing AD, including in children.
Area of Science:
- Immunology
- Dermatology
- Biochemistry
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition.
- Identifying reliable biomarkers for AD severity is crucial for effective management.
- Previous research has explored various correlations between AD severity and biological markers.
Purpose of the Study:
- To review and summarize current knowledge on circulating biomarkers for atopic dermatitis (AD).
- To highlight specific soluble mediators with potential as inflammation markers in AD.
- To include biomarkers relevant to pediatric AD.
Main Methods:
- Literature review of studies investigating biomarkers and AD severity.
- Focus on soluble mediators such as chemokines and cytokines.
- Inclusion of studies on both adult and pediatric populations.
Main Results:
- Certain chemokines, including thymus and activation-regulated chemokine (CCL17) and macrophage-derived chemokine (CCL22), are associated with AD inflammation.
- Cytokines like thymic stromal lymphopoietin are also identified as potential markers.
- These soluble mediators show promise in reflecting the inflammatory status of AD.
Conclusions:
- Circulating biomarkers, particularly specific chemokines and cytokines, can serve as indicators of inflammation in atopic dermatitis.
- These findings support the use of biomarkers for monitoring AD severity, including in pediatric cases.
- Further research may refine the role of these biomarkers in clinical practice.
